Educational Session 1: After CDK4/6 Inhibitors—Advancing Treatment for HR+HER2-negative Metastatic Breast Cancer
Session Details
This educational session focuses on advancing treatment strategies for HR+/HER2-negative metastatic breast cancer after progression on CDK4/6 inhibitors, highlighting next-generation endocrine therapies, emerging resistance-targeting agents, and evolving clinical approaches.
Moderator
Antoinette Tan, Atrium Health, Charlotte, NC
Presentation numberED1-01
Treatment strategies after CDK4/6 inhibitor progression
Mafalda Oliveira, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Presentation numberED1-02
Next generation endocrine agents
Erica Mayer, Dana-Farber Cancer Institute, Boston, MA
Presentation numberED1-03
Emerging agents to overcome CDK4/6 inhibitor resistance
Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia
Advocate
Abigail M Johnston, SurvivingBreastCancer.org, Orlando, FL